Detecting and Monitoring Inflammatory Bowel Disease in Dog (Stool-Immune Test)

Opportunity

Seeking Licensing Partner

IP Status

US Patent: WO 2020/205911

Inventors

Steven Dow
Sirikul Soontararak

Reference No: 19-003
Licensing Manager

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

At a Glance

This Stool Immune diagnostic test uses flow cytometry to quantitate the amount of IgG bound to commensal bacteria in stool specimens from dogs to provide a non-invasive diagnosis of IBD.  Currently, there are no diagnostic tests available to unequivocally diagnose IBD in dogs, other than expensive endoscopic procedure.  The Stool Immune test has demonstrated high sensitivity and high specificity for diagnosing IBD in dogs, with potential to expand to other animals, including humans.

 

Background

Inflammatory Bowel Disease (IBD) is a common disease in dogs with a variety of proposed causes, and can cause vomiting, diarrhea, and weight loss.  Diagnosis of IBD typically requires a combination of laboratory testing and an endoscopic biopsy procedure, which is expensive and requires general anesthesia.  Indirect examination methods, including blood work and radiographs, lack sensitivity and specificity to reliably diagnose the disease. Therefore, novel diagnostic methods are needed to rapidly and correctly diagnose IBD.

Overview

Researchers in the Center for Immune and Regenerative Medicine at Colorado State University have discovered that dogs with IBD develop an immune response against their own gut bacteria, producing high levels of immunoglobulin G (IgG) bound to the surface of gut bacteria, which in turn triggers intestinal inflammation.  Based on this new understanding of the pathogenesis of IBD in dogs, the group has developed a novel diagnostic test (Stool-Immune) for IBD that is rapid, sensitive, and non-invasive.  The test uses flow cytometry to detect and quantitate the amount of IgG bound to gut bacteria, using small stool samples.  The level of IgG binding can be used with high accuracy to distinguish dogs with IBD (high IgG binding) from dogs with healthy GI tracts (low IgG binding).

 
Figure 1. Detection of IgG (red) and IgA (green) responses against commensal gut bacteria in 3 healthy dogs (top row) and in 3 dogs with IBD (bottom row), using fluorescent antibodies.  Dogs with IBD have much more IgG binding to their fecal bacteria than healthy dogs, as evidenced by the red staining bacteria in the bottom panels.
Benefits
  • Use of small stool samples to rapidly diagnose IBD
  • Non-invasive testing, avoids need for endoscopic biopsies
  • Greater sensitivity and specificity than any indirect tests on market currently
  • Potential application in other animal species, including humans